MCD was covered yesterday in the Hedgeye Virtual Portfolio.  Although, I still remain bearish on the name for 2011.


In 1Q11, MCD continued to post industry-leading same-store sales in the U.S. (above my estimate), but now below the rate of inflation the company is experiencing.  While the company has raised prices to absorb some of the commodity inflation, there is a strong possibility this could dampen sales trends given that MCD’s U.S. comps are largely guest-count driven (influenced by significant discounting). 


Compound this scenario with the difficult year-over-year compares MCD U.S. is facing over the summer months and there is heightened risk of sales trends missing consensus in 2Q and 3Q11.  Keith covered the stock today in the Hedgeye Virtual Portfolio and the quantitative risk management set up is illustrated in the chart below.


MCD: MCD VS. YUM - mcd levls chart



One pair-trade that could be of interest if you do not agree with my fundamental thesis on MCD would be short YUM and long MCD.  The valuation spread between the two stocks is the widest it has been for some time on an EV/NTM EBITDA basis.  Additionally, it is typically MCD that has been awarded a higher cash flow multiple by the street.  As the chart below indicates, YUM is currently trading at significant premium to MCD.


YUM's premium multiple is being driven by strong trends in YUM's China division.  To the degree that YUM's +13% same-store sales in China for 1Q is not sustainable, the valuation disparity between the two name could correct.


MCD: MCD VS. YUM - mcd yum spread chart



Howard Penney

Managing Director

Cartoon of the Day: Crash Test Bear

In the past six months, U.S. stock indices are up between +12% and +18%.

read more

GOLD: A Deep Dive on What’s Next with a Top Commodities Strategist

“If you saved in gold over the past 20 to 25 years rather than any currency anywhere in the world, gold has outperformed all these currencies,” says Stefan Wieler, Vice President of Goldmoney in this edition of Real Conversations.

read more

Exact Sciences Up +24% This Week... What's Next? | $EXAS

We remain long Exact Sciences in the Hedgeye Healthcare Position Monitor.

read more

Inside the Atlanta Fed's Flawed GDP Tracker

"The Atlanta Fed’s GDPNowcast model, while useful at amalgamating investor consensus on one singular GDP estimate for any given quarter, is certainly not the end-all-be-all of forecasting U.S. GDP," writes Hedgeye Senior Macro analyst Darius Dale.

read more

Cartoon of the Day: Acrophobia

"Most people who are making a ton of money right now are focused on growth companies seeing accelerations," Hedgeye CEO Keith McCullough wrote in today's Early Look. "That’s what happens in Quad 1."

read more

People's Bank of China Spins China’s Bad-Loan Data

PBoC Deputy Governor Yi says China's non-performing loan problem has “pretty much stabilized." "Yi is spinning. China’s bad-debt problem remains serious," write Benn Steil and Emma Smith, Council on Foreign Relations.

read more

UnderArmour: 'I Am Much More Bearish Than I Was 3 Hours Ago'

“The consumer has a short memory.” Yes, Plank actually said this," writes Hedgeye Retail analyst Brian McGough. "Last time I heard such arrogance was Ron Johnson."

read more

Buffalo Wild Wings: Complacency & Lack of Leadership (by Howard Penney)

"Buffalo Wild Wings has been plagued by complacency and a continued lack of adequate leadership," writes Hedgeye Restaurants analyst Howard Penney.

read more

Todd Jordan on Las Vegas Sands Earnings

"The quarter actually beat lowered expectations. Overall, the mass segment performed well although base mass lagging is a concern," writes Hedgeye Gaming, Lodging & Leisure analyst Todd Jordan on Las Vegas Sands.

read more

An Update on Defense Spending by Lt. Gen Emo Gardner

"Congress' FY17 omnibus appropriation will fully fund the Pentagon's original budget request plus $15B of its $30B supplemental request," writes Hedgeye Potomac Defense Policy analyst Lt. Gen Emerson "Emo" Gardner USMC Ret.

read more

Got Process? Zero Hedge Sells Fear, Not Truth

Fear sells. Always has. Look no further than Zero Hedge.

read more

REPLAY: Review of $EXAS Earnings Call (A Hedgeye Best Idea Long)

Our Healthcare Team made a monster call to be long EXAS - hear their updated thoughts.

read more